CTOs on the Move

Dci Biologicals Wichita Falls

www.dciplasma.com

 
Dci Biologicals Wichita Falls is a Wichita Falls, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.dciplasma.com
  • 1908 9th St Ste D
    Wichita Falls, TX USA 76301
  • Phone: 940.763.0300

Executives

Name Title Contact Details

Similar Companies

Sunnyside Care Ctr

Sunnyside Care Ctr is a Lake Park, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lafayette General Health

Lafayette General Health is Acadianas largest non-profit, community-owned regional health system committed to always delivering excellence. The system has over 4,000 employees, serving the south-central region of Louisiana by aligning with facilities across Acadiana. Lafayette General Health is a founding member of the Ochsner Health Network.

Expression Pathology, Inc

Expression Pathology, Inc is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Gaithersburg, MD. To find more information about Expression Pathology, Inc, please visit www.expressionpathology.com

G3 Medical

G3 Medical is a Asheville, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Relmada

Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.